Articles by Eric Langer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Eric Langer

Eric Langer


is president and managing partner of BioPlan Associates.

Articles
Targeting Different Off-Shore Destinations
September 2, 2014

Annual study shows geographic proximity not a factor in CMO selection.

Study CMO Technical Expertise is Not Enough
September 1, 2014

Sponsors are demanding high levels of professionalism, performance, and effectiveness in managerial areas to accompany CMOs?' technical expertise.

Relationship-building at Top of Mind for Clients
August 2, 2014

Annual study shows CMO technical expertise is not enough.

Cost Is No Longer the Driving Force for Outsourcing
June 29, 2014

With budgets growing, clients see CMOs' costs as less crucial and consider other factors.

Outsourcing No Longer Just for Cost-Cutting
June 2, 2014

With budgets growing, clients see CMOs' costs as less crucial.

Outsourcing Remains Strong In Traditional Areas
May 2, 2014

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Biopharma Outsourcing Activities Update
April 2, 2014

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Top 10 Outsourcing Trends in Biopharmaceutical Manufacturing
February 28, 2014

In biopharmaceutical manufacturing, outsourcing and off-shoring have migrated into much more high-value areas.

Outsourcing Trends in Biopharmaceutical Manufacturing
February 1, 2014

A changing biopharmaceutical industry is going beyond typically outsourced activities and is using CMOs for more challenging processes. Review the top 10 outsourcing trends.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here